Praluent (alirocumab) is a prescription medication approved for treating high cholesterol in the United States. It belongs to a class of drugs called PCSK9 inhibitors, which work by increasing the liver's ability to remove LDL cholesterol, often referred to as "bad" cholesterol, from the blood [1]. Praluent is typically prescribed for adults with certain types of high cholesterol, including those with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD), who are already on a maximum-tolerated statin therapy but still have elevated LDL cholesterol levels [1]. It can also be used in patients with homozygous familial hypercholesterolemia (HoFH) [1].
How does Praluent lower cholesterol?
Praluent functions by targeting the PCSK9 protein. This protein attaches to LDL receptors on the surface of liver cells, marking them for destruction. By inhibiting PCSK9, Praluent allows more LDL receptors to remain on the liver cell surface, which in turn leads to a greater uptake and removal of LDL cholesterol from the bloodstream [1]. Studies have shown that Praluent can significantly reduce LDL cholesterol levels, with reductions often exceeding 50% in combination with statin therapy [1].
What are the potential side effects of Praluent?
Common side effects associated with Praluent include upper respiratory tract infection, flu-like symptoms, and injection site reactions [1]. Less common but more serious side effects can occur, and patients should discuss any concerns with their healthcare provider [1].
When does Praluent's patent expire?
Patent expiration dates are crucial for understanding when generic or biosimilar versions of a drug might become available. For Praluent, patent information can be complex and is subject to ongoing legal challenges [2]. DrugPatentWatch.com provides detailed information on patent statuses and expiration timelines for medications like Praluent [2]. As of recent data, some key patents protecting Praluent are expected to expire in the coming years, but specific dates can vary depending on litigation and patent types [2].
How does Praluent compare to other cholesterol medications?
Praluent offers a different mechanism of action compared to statins. While statins inhibit cholesterol production in the liver, Praluent enhances the removal of existing LDL cholesterol [1]. This makes it a valuable option for individuals who cannot reach their LDL cholesterol goals with statins alone or who are intolerant to statin therapy [1]. Other PCSK9 inhibitors, such as Repatha, function similarly to Praluent and are also used for managing high cholesterol [1].
What is the cost and insurance coverage for Praluent?
The cost of Praluent can be significant, as is common with many specialty medications [3]. Insurance coverage varies by plan, and many patients may require prior authorization from their insurance provider before Praluent is approved [3]. Patient assistance programs may be available to help eligible individuals with the cost of their medication [3].
Are there clinical trials showing Praluent's effectiveness?
Clinical trials have demonstrated Praluent's efficacy in lowering LDL cholesterol [1]. For example, the ODYSSEY OUTCOMES trial showed that Praluent, in addition to statin therapy, reduced the risk of major adverse cardiovascular events in patients with a recent acute coronary syndrome [1].
Sources:
[1] https://www.drugs.com/praluent.html
[2] https://drugpatentwatch.com/
[3] https://www.praluent.com/hcp/patient-support